X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (162) 162
humans (149) 149
hematology (118) 118
middle aged (118) 118
aged (117) 117
male (111) 111
female (109) 109
article (104) 104
adult (100) 100
oncology (91) 91
aged, 80 and over (90) 90
treatment outcome (70) 70
leukemia (66) 66
prognosis (59) 59
young adult (54) 54
hematology, oncology and palliative medicine (52) 52
acute myeloid leukemia (50) 50
antineoplastic combined chemotherapy protocols - therapeutic use (49) 49
cancer (48) 48
chemotherapy (47) 47
leukemia, myeloid, acute - drug therapy (47) 47
adolescent (45) 45
therapy (44) 44
abridged index medicus (43) 43
disease-free survival (40) 40
survival (38) 38
mutation (37) 37
acute myeloid-leukemia (35) 35
leukemia, myeloid, acute - genetics (34) 34
patients (34) 34
survival analysis (33) 33
hemic and lymphatic diseases (32) 32
acute myelogenous leukemia (31) 31
aml (31) 31
leukemia, myeloid, acute - mortality (31) 31
myelodysplastic syndrome (29) 29
cytarabine (28) 28
myeloid leukemia (28) 28
care and treatment (27) 27
minimal residual disease (26) 26
remission induction (26) 26
myelodysplastic syndromes (25) 25
survival rate (25) 25
myelodysplastic syndromes - drug therapy (24) 24
retrospective studies (24) 24
analysis (23) 23
mutations (22) 22
antineoplastic agents - therapeutic use (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
follow-up studies (21) 21
risk factors (21) 21
cytogenetics (20) 20
leukemia, myeloid, acute - pathology (19) 19
recurrence (19) 19
stem cells (19) 19
leukemia, myeloid, acute - diagnosis (18) 18
multivariate analysis (18) 18
bone marrow (17) 17
diagnosis (17) 17
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (17) 17
remission (17) 17
research (17) 17
adults (16) 16
outcomes (16) 16
transplantation (16) 16
adult patients (15) 15
azacitidine - analogs & derivatives (15) 15
bone marrow - pathology (15) 15
clinical trials (15) 15
health aspects (15) 15
medical prognosis (15) 15
myelodysplastic syndromes - mortality (15) 15
age factors (14) 14
dosage and administration (14) 14
precursor cell lymphoblastic leukemia-lymphoma - mortality (14) 14
usage (14) 14
acute lymphocytic-leukemia (13) 13
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
azacitidine - therapeutic use (13) 13
cytarabine - administration & dosage (13) 13
decitabine (13) 13
fms-like tyrosine kinase 3 - genetics (13) 13
myelodysplastic syndromes - pathology (13) 13
neoplasms (13) 13
philadelphia chromosome (13) 13
protein kinase inhibitors - therapeutic use (13) 13
transformation (13) 13
acute lymphoblastic leukemia (12) 12
chromosome aberrations (12) 12
dasatinib (12) 12
drug administration schedule (12) 12
elderly-patients (12) 12
induction chemotherapy (12) 12
intensive chemotherapy (12) 12
kaplan-meier estimate (12) 12
patient outcomes (12) 12
stem-cell transplantation (12) 12
toxicity (12) 12
tyrosine (12) 12
anemia (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 09/2017, Volume 31, Issue 9, pp. 1951 - 1961
The PROTAC (proteolysis-targeting chimera) ARV-825 recruits bromodomain and extraterminal (BET) proteins to the E3 ubiquitin ligase cereblon, leading to... 
TRANSFORMATION | PATHOGENESIS | JAK2 INHIBITOR | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | KINASE | DEGRADATION | ACUTE MYELOID-LEUKEMIA | OVERCOMES RESISTANCE | HEMATOLOGY | CANCER | BRD4 | Antigens, CD34 | Apoptosis - drug effects | Leukemia, Myeloid, Acute - pathology | Humans | Leukemia | Ubiquitin-Protein Ligases - metabolism | Nuclear Proteins - metabolism | Myeloproliferative Disorders - pathology | Thalidomide - pharmacology | Azepines - therapeutic use | Azepines - pharmacology | Transcription Factors - metabolism | Thalidomide - analogs & derivatives | Animals | Tumor Burden - drug effects | Proteolysis | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Mice | Thalidomide - therapeutic use | Chimera | Pyrazoles - pharmacology | Care and treatment | Usage | Messenger RNA | Chimeras (Organisms) | Research | Mass spectrometry | Myeloproliferative disorders | Ubiquitin | Surgical implants | c-Myc protein | In vitro testing | mRNA | Myc protein | Cyclin-dependent kinase 4 | Degradation | Proteins | Biomedical materials | Bcl-x protein | Janus kinase 2 | Biocompatibility | Ubiquitin-protein ligase | CD34 antigen | Cell survival | Stat3 protein | Hemopoiesis | Cytometry | Protein arrays | Depletion | Inhibitors | Ribonucleic acids | Cells (biology) | Bcl protein | Bet protein | In vivo methods and tests | Acute myeloid leukemia | Apoptosis | Secondary AML | PROTAC | protein degradation
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1547 - 1555
Journal Article
Blood, ISSN 0006-4971, 03/2016, Volume 127, Issue 11, pp. 1381 - 1383
In this issue of Blood, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon β (IFNβ)-sodium iodide symporter (NIS)... 
HEMATOLOGY | Vesicular stomatitis Indiana virus - physiology | Animals | Humans | Immunotherapy | Female | B7-H1 Antigen - immunology | Leukemia, Myeloid, Acute - therapy | Oncolytic Virotherapy | Inside
Journal Article
European Journal of Haematology, ISSN 0902-4441, 02/2019, Volume 102, Issue 2, pp. 103 - 110
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2010, Volume 28, Issue 3, pp. 392 - 397
Journal Article
American Journal of Hematology, ISSN 0361-8609, 03/2018, Volume 93, Issue 3, pp. 401 - 407
Introduction: Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), and... 
APOPTOSIS | TREATMENT-NAIVE | RESPONSE CRITERIA | RECOMMENDATIONS | BCL-2 INHIBITOR | HEMATOLOGY | ELDERLY-PATIENTS | MYELODYSPLASTIC SYNDROMES | ABT-199 | CHEMOTHERAPY | INTERNATIONAL WORKING GROUP | Recurrence | Dendritic Cells | Humans | Middle Aged | Salvage Therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Molecular Targeted Therapy | Antimetabolites, Antineoplastic - administration & dosage | Genes, p53 | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Myelodysplastic Syndromes - drug therapy | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Isocitrate Dehydrogenase - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Sulfonamides - pharmacology | Leukemia, Myeloid, Acute - mortality | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Myelodysplastic Syndromes - mortality | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Myelodysplastic Syndromes - genetics | Core Binding Factor Alpha 2 Subunit - genetics | Sulfonamides - administration & dosage | Leukemia, Myeloid, Acute - genetics | Care and treatment | Relapse | Chemotherapy | Dendritic cells | Cytogenetics | Tumor proteins | Diseases | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 240 - 248
Journal Article
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 276 - 281
Journal Article
Seminars in Oncology, ISSN 0093-7754, 10/2011, Volume 38, Issue 5, pp. 682 - 692
Journal Article
Blood, ISSN 0006-4971, 06/2013, Volume 121, Issue 23, pp. 4655 - 4662
Journal Article